Clinical Trial Update: Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating the efficacy of an oral agent SA001 in patients with primary Sjögren's syndrome has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• SA001

Snippet

Sponsor: Samjin Pharmaceutical Co., Ltd. | Conditions: Primary Sjögren's Syndrome (pSS) | Phase 2 | Status: COMPLETED